Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women

[1]  M. Derwahl,et al.  Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules? , 2013, The Journal of endocrinology.

[2]  J. Huot,et al.  17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration , 2012, Breast Cancer Research.

[3]  A. Fierabracci.  Identifying thyroid stem/progenitor cells: advances and limitations. , 2012, The Journal of endocrinology.

[4]  A. Carpi,et al.  Estrogen activity as a preventive and therapeutic target in thyroid cancer. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  A. Romano,et al.  Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  Sheng-Xiang Lin,et al.  The Contribution of 17beta-Hydroxysteroid Dehydrogenase Type 1 to the Estradiol-Estrone Ratio in Estrogen-Sensitive Breast Cancer Cells , 2012, PloS one.

[7]  F Berrino,et al.  Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer , 2011, British Journal of Cancer.

[8]  Michael Biehl,et al.  Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors , 2011, The Journal of clinical endocrinology and metabolism.

[9]  Eun Jig Lee,et al.  Metabolic alteration of urinary steroids in pre- and post-menopausal women, and men with papillary thyroid carcinoma , 2011, BMC Cancer.

[10]  B. Chung,et al.  A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis[S] , 2011, Journal of Lipid Research.

[11]  R. Khalil,et al.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. , 2010, Current drug metabolism.

[12]  E. Taioli,et al.  Urinary estrogen metabolites in women at high risk for breast cancer. , 2009, Carcinogenesis.

[13]  S. Devesa,et al.  Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005 , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  T. Veenstra,et al.  A Liquid Chromatography-Mass Spectrometry Method for the Simultaneous Measurement of 15 Urinary Estrogens and Estrogen Metabolites: Assay Reproducibility and Interindividual Variability , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  R. Valcavi,et al.  Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women , 2008, Menopause.

[16]  Krzysztof Fujarewicz,et al.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping , 2007, Endocrine-related cancer.

[17]  R. Paschke,et al.  Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. , 2007, Endocrine reviews.

[18]  E. Kebebew,et al.  Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms , 2006, Cancer.

[19]  D. Sepkovic,et al.  A Hormonal Association between Estrogen Metabolism and Proliferative Thyroid Disease , 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[20]  Frederick A Meier,et al.  Errors in thyroid gland fine-needle aspiration. , 2006, American journal of clinical pathology.

[21]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[22]  M. Landström,et al.  2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells. , 2006, Thyroid : official journal of the American Thyroid Association.

[23]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[24]  Jennifer Shoemaker,et al.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. , 2004, The Journal of clinical investigation.

[25]  R. A’Hern,et al.  Long‐term results in elderly patients with differentiated thyroid carcinoma , 2003, Cancer.

[26]  S. Inoue,et al.  Estrogen Receptors (α and β) and 17β-Hydroxysteroid Dehydrogenase Type 1 and 2 in Thyroid Disorders: Possible In Situ Estrogen Synthesis and Actions , 2003, Modern Pathology.

[27]  R. Kraemer,et al.  Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. , 2003, Fertility and sterility.

[28]  P. Neuhaus,et al.  The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors , 2001, Journal of Cancer Research and Clinical Oncology.

[29]  M. Pike,et al.  Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[30]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[31]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[32]  H. Bradlow,et al.  16α‐Hydroxylation of Estradiol: A Possible Risk Marker for Breast Cancer , 1986 .

[33]  H. Husdan,et al.  Estimation of creatinine by the Jaffe reaction. A comparison of three methods. , 1968, Clinical chemistry.

[34]  이은직,et al.  Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women , 2013 .

[35]  C. Guillemette,et al.  Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. , 2011, The Journal of clinical endocrinology and metabolism.

[36]  A. Conney,et al.  Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.

[37]  Pelayo Correct,et al.  Endocrine gland cancer , 1995, Cancer.